TY - JOUR
T1 - Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients
T2 - A Prospective Cohort Study
AU - Oulhaj, Abderrahim
AU - Alsuwaidi, Ahmed R.
AU - Suliman, Abubaker
AU - Gasmelseed, Huda
AU - Khan, Shaima
AU - Alawi, Shamma
AU - Hukan, Yaman
AU - George, Junu
AU - Alshamsi, Fayez
AU - Sheikh, Farrukh
AU - Babiker, Zahir Osman Eltahir
AU - Prattes, Juergen
AU - Sourij, Harald
N1 - Funding Information:
This work was supported by a research grant from the College of Medicine and Health Sciences at the United Arab Emirates University .
Publisher Copyright:
© 2021 The Author(s)
PY - 2021/6
Y1 - 2021/6
N2 - Objective: To examine the association between plasma levels of the soluble urokinase plasminogen activator receptor (suPAR) and the incidence of severe complications of COVID-19. Methods: 403 RT-PCR-confirmed COVID-19 patients were recruited and prospectively followed-up at a major hospital in the United Arab Emirates. The primary endpoint was time from admission until the development of a composite outcome, including acute respiratory distress syndrome (ARDS), intensive care unit (ICU) admission, or death from any cause. Patients discharged alive were considered as competing events to the primary outcome. Competing risk regression was used to quantify the association between suPAR and the incidence of the primary outcome. Results: 6.2% of patients experienced ARDS or ICU admission, but none died. Taking into account competing risk, the incidence of the primary outcome was 11.5% (95% confidence interval [CI], 6.7–16.3) in patients with suPAR levels >3.91 ng/mL compared to 2.9% (95% CI, 0.4–5.5) in those with suPAR ≤3.91 ng/mL. Also, an increase by 1 ng/mL in baseline suPAR resulted in a 58% rise in the hazard of developing the primary outcome (hazard ratio 1.6, 95% CI, 1.2–2.1, p = 0.003). Conclusion: suPAR has an excellent prognostic utility in predicting severe complications in hospitalised COVID-19 patients.
AB - Objective: To examine the association between plasma levels of the soluble urokinase plasminogen activator receptor (suPAR) and the incidence of severe complications of COVID-19. Methods: 403 RT-PCR-confirmed COVID-19 patients were recruited and prospectively followed-up at a major hospital in the United Arab Emirates. The primary endpoint was time from admission until the development of a composite outcome, including acute respiratory distress syndrome (ARDS), intensive care unit (ICU) admission, or death from any cause. Patients discharged alive were considered as competing events to the primary outcome. Competing risk regression was used to quantify the association between suPAR and the incidence of the primary outcome. Results: 6.2% of patients experienced ARDS or ICU admission, but none died. Taking into account competing risk, the incidence of the primary outcome was 11.5% (95% confidence interval [CI], 6.7–16.3) in patients with suPAR levels >3.91 ng/mL compared to 2.9% (95% CI, 0.4–5.5) in those with suPAR ≤3.91 ng/mL. Also, an increase by 1 ng/mL in baseline suPAR resulted in a 58% rise in the hazard of developing the primary outcome (hazard ratio 1.6, 95% CI, 1.2–2.1, p = 0.003). Conclusion: suPAR has an excellent prognostic utility in predicting severe complications in hospitalised COVID-19 patients.
KW - Acute respiratory distress syndrome
KW - All-cause mortality
KW - COVID-19
KW - Intensive care admission
KW - Urokinase plasminogen activator
UR - http://www.scopus.com/inward/record.url?scp=85106241667&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106241667&partnerID=8YFLogxK
U2 - 10.1016/j.ijid.2021.04.026
DO - 10.1016/j.ijid.2021.04.026
M3 - Article
C2 - 33862208
AN - SCOPUS:85106241667
SN - 1201-9712
VL - 107
SP - 188
EP - 194
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
ER -